These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 25723165)

  • 1. Structural basis for Marburg virus neutralization by a cross-reactive human antibody.
    Hashiguchi T; Fusco ML; Bornholdt ZA; Lee JE; Flyak AI; Matsuoka R; Kohda D; Yanagi Y; Hammel M; Crowe JE; Saphire EO
    Cell; 2015 Feb; 160(5):904-912. PubMed ID: 25723165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of human antibody-mediated neutralization of Marburg virus.
    Flyak AI; Ilinykh PA; Murin CD; Garron T; Shen X; Fusco ML; Hashiguchi T; Bornholdt ZA; Slaughter JC; Sapparapu G; Klages C; Ksiazek TG; Ward AB; Saphire EO; Bukreyev A; Crowe JE
    Cell; 2015 Feb; 160(5):893-903. PubMed ID: 25723164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
    Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
    J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macaque antibodies targeting Marburg virus glycoprotein induced by multivalent immunization.
    Janus BM; Wang R; Cleveland TE; Metcalf MC; Lemmer AC; van Dyk N; Jeong S; Astavans A; Class K; Fuerst TR; Ofek G
    J Virol; 2024 Jul; 98(7):e0015524. PubMed ID: 38832790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies.
    Bornholdt ZA; Ndungo E; Fusco ML; Bale S; Flyak AI; Crowe JE; Chandran K; Saphire EO
    mBio; 2016 Feb; 7(1):e02154-15. PubMed ID: 26908579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies.
    Ilinykh PA; Huang K; Santos RI; Gilchuk P; Gunn BM; Karim MM; Liang J; Fouch ME; Davidson E; Parekh DV; Kimble JB; Pietzsch CA; Meyer M; Kuzmina NA; Zeitlin L; Saphire EO; Alter G; Crowe JE; Bukreyev A
    Cell Host Microbe; 2020 Jun; 27(6):976-991.e11. PubMed ID: 32320678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
    Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
    J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease.
    Babirye P; Musubika C; Kirimunda S; Downing R; Lutwama JJ; Mbidde EK; Weyer J; Paweska JT; Joloba ML; Wayengera M
    BMC Infect Dis; 2018 Oct; 18(1):498. PubMed ID: 30285648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
    Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
    Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk.
    King LB; West BR; Moyer CL; Gilchuk P; Flyak A; Ilinykh PA; Bombardi R; Hui S; Huang K; Bukreyev A; Crowe JE; Saphire EO
    Nat Commun; 2019 Apr; 10(1):1788. PubMed ID: 30996276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of the Marburg virus GP2 core domain in its postfusion conformation.
    Koellhoffer JF; Malashkevich VN; Harrison JS; Toro R; Bhosle RC; Chandran K; Almo SC; Lai JR
    Biochemistry; 2012 Oct; 51(39):7665-75. PubMed ID: 22935026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Marburg virus neutralizing antibodies from virus-naïve human antibody repertoires using large-scale structural predictions.
    Bozhanova NG; Sangha AK; Sevy AM; Gilchuk P; Huang K; Nargi RS; Reidy JX; Trivette A; Carnahan RH; Bukreyev A; Crowe JE; Meiler J
    Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31142-31148. PubMed ID: 33229516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.
    Keshwara R; Hagen KR; Abreu-Mota T; Papaneri AB; Liu D; Wirblich C; Johnson RF; Schnell MJ
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
    Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
    J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies.
    Murin CD; Gilchuk P; Ilinykh PA; Huang K; Kuzmina N; Shen X; Bruhn JF; Bryan AL; Davidson E; Doranz BJ; Williamson LE; Copps J; Alkutkar T; Flyak AI; Bukreyev A; Crowe JE; Ward AB
    Cell Rep; 2021 Apr; 35(2):108984. PubMed ID: 33852862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.
    Fusco ML; Hashiguchi T; Cassan R; Biggins JE; Murin CD; Warfield KL; Li S; Holtsberg FW; Shulenin S; Vu H; Olinger GG; Kim DH; Whaley KJ; Zeitlin L; Ward AB; Nykiforuk C; Aman MJ; Berry JD; Saphire EO
    PLoS Pathog; 2015 Jun; 11(6):e1005016. PubMed ID: 26115029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Insights into Reovirus σ1 Interactions with Two Neutralizing Antibodies.
    Dietrich MH; Ogden KM; Katen SP; Reiss K; Sutherland DM; Carnahan RH; Goff M; Cooper T; Dermody TS; Stehle T
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
    Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of specific antibody responses to the six species of ebola and Marburg viruses by multiplexed protein microarrays.
    Kamata T; Natesan M; Warfield K; Aman MJ; Ulrich RG
    Clin Vaccine Immunol; 2014 Dec; 21(12):1605-12. PubMed ID: 25230936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
    Lennemann NJ; Rhein BA; Ndungo E; Chandran K; Qiu X; Maury W
    mBio; 2014 Jan; 5(1):e00862-13. PubMed ID: 24473128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.